Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Conditions
Keywords
motor neurone disease, amyotrophic lateral sclerosis, IC14 [anti-CD14 (cluster of differentiation 14) monoclonal antibody], monoclonal antibody, anti-CD14
Brief summary
Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses. Patients must be within 3 years of MND diagnosis and have adequate respiratory function. Safety, tolerability, immunogenicity, and PK/PD will be measured. To evaluate feasibility of the endpoints, additional endpoints of ALSFRS-R, respiratory function tests, disease biomarkers and patient-reported outcomes will be measured.
Detailed description
The objectives of this study are to determine: * The safety, tolerability and immunogenicity of IC14 in patients with motor neurone disease (MND). * The pharmacokinetics and pharmacodynamics of IC14 in patients with MND. * The preliminary effect of IC14 on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) in patients with MND. * The preliminary effect of IC14 on forced vital capacity (FVC) and other clinical markers of disease severity in patients with MND. * The preliminary effect of IC14 on patient-reported outcome measures. * The preliminary effect of IC14 on disease biomarkers. Ten patients with MND will be sequentially assigned to receive one of two dose regimens of IC14 in an unblinded manner: * For the initial 3 patients: IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses. * For the subsequent 7 patients: IC14 at a dosage of 4 mg/kg on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 for 4 total doses. Study participation will continue until 28 days after the last dose of study drug.
Interventions
BIOLOGICALIC14
chimeric monoclonal antibody against human IC14
Sponsors
Royal Brisbane and Women's Hospital
Implicit Bioscience
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-label, dose-escalation, safety and pharmacokinetic
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
A patient must fulfill all of the following criteria to be eligible for enrollment: 1. Signed informed consent prior to initiation of any study-specific procedures. 2. Familial or sporadic motor neurone disease (MND) defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations. 3. First symptoms of MND within 3 years of informed consent. 4. Age between 18 and 75 years at time of informed consent. 5. Seated Forced Vital Capacity (FVC) ≥ 65% of predicted value. 6. Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to screening visit. 7. Adequate bone marrow reserve, renal and liver function: * absolute neutrophil count ≥ 1500/µL * lymphocyte count \< 48% * platelet count ≥ 150,000/µL * hemoglobin ≥ 11 g/dL * Estimated glomerular filtration rate (eGFR) \>= 40 mL/min/1.73 m2 * Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) ≤ 2x upper imit of normal (ULN), total bilirubin ≤ 1.5x ULN * serum albumin ≥ 2.8 g/dL 8. Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: * Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or * Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or * Stable hormonal contraception for at least 3 months prior to study through study completion; or * Surgical sterilization (vasectomy) of male partner at least 6 months prior to study. 9. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses. 10. Males with female partners of childbearing potential must use contraception through study completion. 11. Medically safe to have lumbar puncture to collect cerebrospinal fluid. 12. Able to give informed consent and able to comply with all study visits and all study procedures.
Exclusion criteria
A patient fulfilling any of the following criteria at screening is to be excluded from enrollment in the study: 1. Dependence on mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening. 2. Treatment with a drug or device within the last 30 days that has not received regulatory approval. 3. Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-α, interferon-β-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation). 4. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections or major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks. 5. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. 6. Presence of any of the following clinical conditions: * Bleeding diathesis or receipt of anticoagulants within 7 days (or any other clinical condition that would, in the opinion of the investigator, place the patient at increased risk during lumbar puncture). * History of one or more of the following: cardiac insufficiency (New York Heart Association \[NYHA\] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure \> 170 mmHg or diastolic blood pressure \> 110 mmHg). * History of venous thromboembolic disease within 12 months, myocardial infarction, or cerebrovascular accident. * Unstable pulmonary, renal, hepatic, endocrine or hematologic disease. * Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. * Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma). * Human immunodeficiency virus infection or other immunodeficiency illness. * Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days. * Drug abuse or alcoholism within the past 12 months. * Significant neuromuscular disease other than MND. * Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy. 7. Pregnancy or breastfeeding. 8. Deprivation of freedom by administrative or court order.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent adverse events (safety, tolerability) | one month | Number of participants with treatment-emergent adverse events (safety, tolerability) classified by MedDRA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory function | one month | Treatment-related change in percent normal Forced Vital Capacity \[0% (worst) to 100% (best)\] |
| Muscle function | one month | Treatment-related change in percent normal Sniff Nasal Pressure \[0% (worst) to 100% (best)\] |
| Quality of life measured by ALSSQOL | one month | Treatment-related change in Amyotrophic Lateral Sclerosis Specific Quality of Life - Revised (ALSSQOL-R) \[0 (worst) to 460 (best)\] |
| Patient-reported outcome | one month | Treatment-related change Edinburgh Cognitive and Behavioural Assessment Score (ECAS) \[0 (worst) to 136 (best)\] |
| Maximum Plasma Concentration (Cmax) | one month | Maximum serum IC14 concentration (micrograms per milliliter) |
| Treatment-related change in ALSFRS-R functional scale | one month | Treatment-related change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) \[0 (worst) to 48 (best)\] |
| Monocyte CD14 Receptor Occupancy | one month | Treatment-related change in percent monocyte CD14 receptor occupancy as a pharmacodynamic marker |
| Urinary p75 neurotrophin receptor (biomarker) | one month | Treatment-related change in urinary concentration of urinary p75 neurotrophin receptor (NTR) (nanograms per milligram creatinine) |
| Neurofilament (biomarker) | one month | Treatment-related change in concentration of neurofilament (picograms per milliliter) |
| Anti-drug antibodies | one month | Development of human anti-monoclonal antibodies following treatment |
| Area Under the Curve (AUC) | one month | Area Under the Curve for serum IC14 (microgram x hr/mL) |
Countries
Australia
Outcome results
None listed